Dr. Sheldon Chen, MD

Dr. Chen practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Chen's NPI, 1003921495, was assigned on August 19, 2006. Dr. Chen graduated from Baylor College Of Medicine in 1994. Dr. Chen holds Texas license Q1964.

Dr. Chen's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Chen's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chen practices. Vendor and product names are available with a free account.

Nephrology is Dr. Chen's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Chen is board certified in nephrology by the American Board of Internal Medicine. Dmand AI has Dr. Chen's licenses on file in 13 states: Texas, Florida, Arizona, Tennessee, Washington, Alabama, Georgia, Louisiana, Mississippi, Oklahoma, Illinois, Pennsylvania and Michigan.

Dmand AI lists acute kidney failure, chronic kidney disease, fluid and electrolyte imbalances, hypercalcemia, kidney cysts and parathyroid gland disorder among the conditions Dr. Chen treats.

CMS data shows 957 Medicare services from Dr. Chen across 9 procedure codes in 2024, for 307 Medicare patients. Medicare paid $89,987 for them.

CMS counts 307 Medicare patients who saw Dr. Chen in 2024. The largest group is 65 to 74, with 143 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 7% are also on Medicaid. Their average risk score is 4.02, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chen's median patient age at 71, with 39% women.

In 2024, Dr. Chen wrote 56 Medicare Part D claims. 100% of them were for generic drugs. CMS names the drug for 13 of them, across 1 drug with 11 or more claims each, at $83 in total drug cost. In 2023, CMS named 24 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Chen for performance year 2024, reported as part of a group. Dr. Chen accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Chen as offering telehealth.

Dmand AI links 34 papers to Dr. Chen, published from 2006 to 2024. 2006 was the busiest year, with 3. The most frequent topics are Diabetic Nephropathies, Kidney and Creatinine. Dr. Chen has published most often in Physiol Rep. Dr. Chen's most frequent co-authors are Nelson Leung, MD, Ala Abudayyeh, MD and Shuchi Md Anand, MD.

CMS Open Payments shows 57 general payments to Dr. Chen from 18 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 63% of the total. La Jolla Pharmaceutical Company paid the most, $2,136.

Dmand AI lists 1 award for Dr. Chen.

Dr. Chen graduated from Baylor College Of Medicine in 1994. Dr. Chen is a member of AOA, ASN and American Society of Onco-Nephrology.

Dr. Chen is in network with 9 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. POS plans come from the most carriers, 5. Check the plan with the practice before a visit.